文献速递神经肿瘤

II型RAF抑制剂托沃拉非尼在复发/难治性视路胶质瘤儿童中的影像学与视力反应:FIREFLY-1试验

Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.
PubMed 文献 · Neuro Oncol · 2025-01-01

FIREFLY-1为2期试验,评估托沃拉非尼(420 mg/m2每周一次,最大600 mg)在BRAF改变的复发/难治性儿童低级别胶质瘤中的疗效与安全性。事后分析纳入42例视路胶质瘤患者,按RANO-HGG、RAPNO和RANO-LGG标准的总体缓解率分别为64%、50%和55%,80%患者视力保持稳定,31%视力改善。

要点

  • 视路胶质瘤亚组按RANO-HGG、RAPNO和RANO-LGG标准的总体缓解率分别为64%、50%和55%。
  • 80%患者视力保持稳定,31%视力改善;按眼评估87%保持稳定,27%改善。
  • 视路胶质瘤亚组安全性与FIREFLY-1总体安全性分析集相似。

核心结论

  • 托沃拉非尼在复发/难治性BRAF改变视路胶质瘤中跨影像学评估标准显示抗肿瘤活性,且总体耐受良好;多数患者视力保持稳定或改善。

研究设计与样本

  • FIREFLY-1为2期试验,评估托沃拉非尼(420 mg/m2每周一次;最大600 mg)在BRAF改变的复发/难治性儿童低级别胶质瘤中的疗效(第1臂,n=77)、安全性和耐受性(第1/2臂)。
  • 本事后分析纳入第1臂中视路胶质瘤患者,分析抗肿瘤活性与视力,抗肿瘤活性由独立评估按RANO-HGG、RAPNO和RANO-LGG标准评定,数据截止2023年6月5日。

主要发现

  • 77例中42例为视路胶质瘤,42例中35例有至少2次视力评估。
  • 视路胶质瘤亚组按RANO-HGG、RAPNO和RANO-LGG标准的总体缓解率分别为64%、50%和55%,临床获益率分别为95%、88%和90%。
  • 按患者评估,80%患者视力保持稳定,31%视力改善;按眼评估,87%保持稳定,27%改善。
  • 第1臂视路胶质瘤亚组的安全性与FIREFLY-1总体安全性分析集相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Due to their anatomical locations, optic pathway gliomas (OPGs) can rarely be cured by resection. Given the importance of preserving visual function, we analyzed radiological and visual acuity (VA) outcomes for the type II RAF inhibitor tovorafenib in the OPG subgroup of the phase 2 FIREFLY-1 trial. METHODS: FIREFLY-1 investigated the efficacy (arm 1, n = 77), safety, and tolerability (arms 1/2) of tovorafenib (420 mg/m2 once weekly; 600 mg maximum) in patients with BRAF-altered relapsed/refractory pediatric low-grade glioma (pLGG). In this post hoc analysis, anti-tumor activity and VA were analyzed in arm 1 patients with OPG. Anti-tumor activity was independently assessed per Response Assessment in Neuro-Oncology high-grade glioma (RANO-HGG), Response Assessment in Pediatric Neuro-Oncology-LGG (RAPNO), and RANO-LGG criteria. The data cutoff was June 5, 2023. RESULTS: Forty-two of 77 patients had OPGs; 35 of 42 had ≥2 VA assessments. The overall response rate in the OPG subgroup according to RANO-HGG, RAPNO, and RANO-LGG criteria were 64%, 50%, and 55%, with clinical benefit rates of 95%, 88%, and 90%, respectively. VA per patient was preserved for 80% of patients; 31% demonstrated improved VA; VA per eye was preserved in 87%, with 27% improving. The safety profile in the arm 1 OPG subgroup was similar to the overall FIREFLY-1 safety analysis set. CONCLUSIONS: Tovorafenib demonstrated anti-tumor activity in relapsed/refractory BRAF-altered OPG across radiological assessment criteria and was generally well tolerated. Importantly, vision remained stable or improved in most patients.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Nysom K, Kilburn LB, Leary SES, et al. Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial. Neuro Oncol. 2025. PMID: 39700439. doi:10.1093/neuonc/noae274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。